Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSHU | ISIN: US15673T1007 | Ticker-Symbol:
NASDAQ
24.04.25
15:30 Uhr
0,540 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CENTURY THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CENTURY THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur CENTURY THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:06H.C. Wainwright maintains Buy rating on Century Therapeutics stock1
15.04.Century Therapeutics, Inc.: Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 202512
03.04.H.C. Wainwright cuts Century Therapeutics target to $24
21.03.Demystifying Century Therapeutics: Insights From 4 Analyst Reviews1
21.03.Guggenheim cuts Century Therapeutics target to $5, keeps Buy rating2
CENTURY THERAPEUTICS Aktie jetzt für 0€ handeln
20.03.Century Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
19.03.Century Therapeutics GAAP EPS of -$1.61 misses by $0.23, revenue of $6.59M beats by $3.24M2
19.03.Century Therapeutics, Inc. - 8-K, Current Report1
19.03.Century Therapeutics, Inc. - 10-K, Annual Report1
19.03.Century Therapeutics, Inc.: Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update100Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated...
► Artikel lesen
28.02.Century Therapeutics, Inc. - 8-K, Current Report1
22.01.4 Analysts Have This To Say About Century Therapeutics4
21.01.Century Therapeutics startet Zelltherapie-Studie für Autoimmunerkrankungen2
21.01.Century Therapeutics launches cell therapy trial for autoimmune diseases1
21.01.Century Therapeutics, Inc.: Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned ...135- Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg - -...
► Artikel lesen
13.01.Century Therapeutics, Inc. - 8-K, Current Report-
13.12.24Century Therapeutics, Inc. - 8-K, Current Report1
28.11.24Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4%2
05.11.24Century Therapeutics, Inc.: Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates169- Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy -- Overall response rate (ORR) of 83%...
► Artikel lesen
05.11.24Century Therapeutics, Inc.: Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting3
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1